7 citations
,
April 2024 in “Skin Research and Technology” ChatGPT effectively addresses psoriasis concerns but can't replace doctors.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
People with psoriasis have more health problems, including autoimmune diseases, than those without it.
11 citations
,
January 2010 in “European Journal of Dermatology” Contact immunotherapy helped hair regrow in a patient with both alopecia and psoriasis.
Men with both baldness and scalp psoriasis often don't have psoriasis on bald spots.
2 citations
,
January 2020 in “Skin Appendage Disorders” Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
1 citations
,
December 2022 in “PubMed” Psoriasis treatments don't raise severe COVID-19 risk, except for acitretin.
July 2025 in “Journal of Investigative Dermatology” Systemic therapy may reduce male infertility in psoriasis patients.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
January 2020 in “Benha Journal of Applied Sciences” People with psoriasis have higher levels of Apelin-13 in their blood than healthy people.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
January 2018 in “SOJ microbiology & infectious diseases” Etanercept, a psoriasis treatment, caused hair loss in a patient.
June 2017 in “Journal of Clinical and Health Sciences” A woman developed folliculitis after long-term acitretin treatment for pustular psoriasis.
A woman developed folliculitis after taking acitretin for psoriasis, which was treated with skin dressing and antibiotics.
60 citations
,
September 2004 in “Pediatric Dermatology” A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.
7 citations
,
September 2021 in “Dermatology and Therapy” Vaccination is crucial for psoriasis patients on immunosuppressive therapy to manage COVID-19 risks.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
7 citations
,
April 2013 in “International Journal of Rheumatic Diseases” Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
April 2023 in “Journal of Investigative Dermatology” Narrowband Ultraviolet B treatment can significantly reduce anxiety in psoriasis patients, but it doesn't significantly affect depression.
May 2015 in “Journal of The American Academy of Dermatology” Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.
6 citations
,
January 2010 in “PubMed” Scalp psoriasis is linked to impaired hair growth with more hair in the resting phase.
1 citations
,
April 2024 in “Skin research and technology” Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
November 2024 in “Journal of Investigative Dermatology” Polygenic Score can help predict severe psoriasis and psoriatic arthritis.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
September 2023 in “Journal of the American Academy of Dermatology” Including special area involvement helps identify more psoriasis patients who may need systemic treatment.